Press Releases

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 5, 2023-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 7,500 restricted stock units (RSUs) to one new

Jan 05, 2023

Read More

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.

You are now leaving AVROBIO’s website.

The third party website to which you will be directed is not affiliated with AVROBIO, and AVROBIO assumes no responsibility for information or statements on third parties’ websites. Thank you for visiting avrobio.com.

Continue to URL Cancel